Delving into the Latest Updates on CD33-CART(Guangzhou Peptide Kang Pharmaceutical Technology) with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms-

Target

CD33

Action

modulators

Mechanism

CD33 modulators(Myeloid cell surface antigen CD33 modulators)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Guangzhou Peptide Medical Technology Co., Ltd.

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseDiscontinuedClinical

First Approval Date-

Regulation-

Acute myeloid leukemia (AML) is a group of genetically highly heterogeneous malignant disease . The disease is the most common type of adult acute leukemia. Overall survival (OS) was less than 50% in 5 years. Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy. The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, although it start late, several clinical trials have been register in ClinicalTrials.gov.

Start Date01 Apr 2018

Sponsor / Collaborator